Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15172 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Meir Schechter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Patients with type 2 diabetes (T2D) have a high incidence of hospitalizations that reduce patients' quality of life and are translated into a significant burden on healthcare systems, accompanied by increased costs.1,2 Randomized controlled trials (RCTs) showed that sodiumglucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular events, heart failure (HF) hospitalizations, and kidney outcomes in patients with T2D, HF, or chronic kidney disease (CKD).3 In some of these RCTs, SGLT2 inhibitors also modestly reduced the risk for any hospitalization.[4][5][6][7][8][9][10][11] However, these studies included patients with T2D and high cardiovascular risk, [4][5][6]11 or patients with CKD with and without T2D.8,9 Whether SGLT2 inhibitor use is associated with a lower risk for any hospitalization in a general population of patients with T2D, especially patients without CKD, is unknown.This was an observational, retrospective, cohort study of data from Maccabi Healthcare Services (MHS), Israel's seconds largest Health Maintenance Organization.We assessed the association of long-term, real-world use of SGLT2 inhibitors, versus that of dipeptidyl peptidase-4 (DPP-4) inhibitors, with risk for hospitalization in patients with T2D lacking evidence of CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel.
- School of Public Health Sackler, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Meir Schechter, Cheli Melzer Cohen, Ofri Mosenzon
Förderung
- Boehringer Ingelheim
Zitieren
APA
Schechter, M., Melzer Cohen, C., Zelter, T., Yanuv, I., Rozenberg, A., Chodick, G., Karasik, A., & Mosenzon, O. (2023). Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15172
Vancouver
Schechter M, Melzer Cohen C, Zelter T, Yanuv I, Rozenberg A, Chodick G, et al. Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15172
BibTeX
@article{Schechter2023,
author = {Schechter, Meir and Melzer Cohen, Cheli and Zelter, Tamir and Yanuv, Ilan and Rozenberg, Aliza and Chodick, Gabriel and Karasik, Avraham and Mosenzon, Ofri},
title = {Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15172}
}
EUVIMED